Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Guide: Dosing, Results, Calculator & Side Effects (2026)
hubThe ultimate retatrutide resource hub. Learn about this investigational triple-agonist, its remarkable Phase 2 results, dosing schedules, microdosing protocols, and use our free calculator to plan your journey.
Retatrutide (GLP-3) Dosing Guide: 2mg to 12mg Protocol
guidesComplete GLP-3 retatrutide dosage guide covering the 2mg to 12mg weekly titration protocol, printable dosing chart, half-life pharmacokinetics, weight loss results from clinical trials, side effects management, and a free interactive dosing calculator.
GLP-3 vs GLP-1: Triple vs Single Agonist Comparison Chart (2026)
comparison"GLP-3" is informal shorthand for triple-agonist drugs like retatrutide. This chart maps GLP-1 mono, GIP/GLP-1 dual, and triple agonists side by side on mechanism, FDA status, and trial weight loss.